There are a lot of shareholders that consistently want detail after detail presented to them about every program at AMBS. This program was pretty much presented in detail this morning giving confidence it is about to be initiated and they are moving forward with ADHD very soon behind it. In regard to Eltoprazine, the PR this morning is about as much detail as they could possibly ever give. What more is needed. It is a positive news event. These 2 indications are MASSIVE. If we didn't have a near term candidate like Lympro, I would yawn, but we do have Lympro that will be generating revenue while Eltoprazine and MANF are being developed.

Honestly, after more thought, I would like there to be no more news until after the shareholders meeting. Let the stock price fall. Then I would like GC to drop the nuke of all PR's the day after. Lympro data or a joint PR that announced data and a partner. There is no point in selling due to anything happening at the shareholders meeting. Data will be released by next week at the latest and if there is selling they miss out...